These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 7243799)

  • 1. Deterioration of renal function in non-dialytic uraemics caused by 1 alpha (OH)D3 which was not attributable to hypercalcaemia.
    Yoshiyama N; Akiba T; Matsui N; Iwamoto H; Ogura M; Nakagawa S; Takeuchi J
    Proc Eur Dial Transplant Assoc; 1980; 17():569-74. PubMed ID: 7243799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol.
    Christiansen C; Rødbro P; Christensen MS; Hartnack B; Transbøl I
    Lancet; 1978 Sep; 2(8092 Pt 1):700-3. PubMed ID: 80633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased renal function in association with administration of 1,25-dihydroxyvitamin D3 to patients with stable, advanced renal failure.
    Christiansen C; Røodbro P; Christensen MS; Naestoft J; Hartnack B; Transbøol I
    Contrib Nephrol; 1980; 18():139-46. PubMed ID: 6243527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1-alpha-hydroxyvitamin D3 in chronic renal failure. A potent analogue of the kidney hormone, 1,25-dihydroxycholecalciferol.
    Chan JC; Oldham SB; Holick MF; DeLuca HF
    JAMA; 1975 Oct; 234(1):47-52. PubMed ID: 1174223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man.
    Brickman AS; Coburn JW; Friedman GR; Okamura WH; Massry SG; Norman AW
    J Clin Invest; 1976 Jun; 57(6):1540-7. PubMed ID: 932193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF
    Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
    Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
    Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of 1 alpha-hydroxy vitamin D3 (0.25 micrograms/day) and calcium carbonate on patients with chronic renal failure at the predialytic stage.
    Okada K; Nagura Y; Takahashi S; Hatano M
    Nihon Jinzo Gakkai Shi; 1989 Jun; 31(6):657-60. PubMed ID: 2795995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone.
    Birkenhäger-Frenkel DH; Pols HA; Zeelenberg J; Eijgelsheim JJ; Schot R; Nigg AL; Weimar W; Mulder PG; Birkenhäger JC
    J Bone Miner Res; 1995 Feb; 10(2):197-204. PubMed ID: 7754799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 1-alpha OH D3 therapy in uremic patients in conservative or dialytic treatment.
    Lamperi S; Vagge R
    Int J Artif Organs; 1979 Sep; 2(5):243-7. PubMed ID: 478681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing renal bone disease in moderate renal failure with CaCO3 and 25(OH) vitamin D3.
    Fournier A; Idrissi A; Sebert JL; Gueris J; Garabedian M; Renaud H; Westeel PF
    Kidney Int Suppl; 1988 Mar; 24():S178-9. PubMed ID: 3163044
    [No Abstract]   [Full Text] [Related]  

  • 13. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH)3.
    Demontis R; Leflon A; Fournier A; Tahiri Y; Herve M; Moriniere P; Abdull-Massih Z; Atik H; Belbrik S; Renaud H
    Clin Nephrol; 1986 Sep; 26(3):146-9. PubMed ID: 3769230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of 1-alpha-hydroxycholecalciferol (1 alpha-OH/D3) and 24,25-dihydroxycholecalciferol (24, 25-OH)2D3) on calcium and phosphorus metabolism in chronic renal failure].
    Galus K; Szymendera J; Jelińska S; Schabowska M; Jelonek A
    Pol Arch Med Wewn; 1979 Feb; 61(2):105-12. PubMed ID: 440977
    [No Abstract]   [Full Text] [Related]  

  • 16. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
    Madsen S
    Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of treatment with dihydrotachysterol on renal function in patients with chronic renal failure.
    Cordy PE; Hodsman AB
    Miner Electrolyte Metab; 1984; 10(5):281-5. PubMed ID: 6493156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative therapeutic effects of vitamin D3 and its derivatives on experimental renal osteodystrophy.
    Fukushima M; Niki R; Ohkawa H; Shimizu T; Matsunaga I; Nakano H; Takagaki Y; Nishii Y; Okano K; Suda T
    Endocrinology; 1980 Jul; 107(1):328-33. PubMed ID: 6247140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 1 alpha-hydroxyvitamin D3 and dietary calcium and phosphate on the aortic mineral content in rabbits with mild azotemia.
    Tvedegaard E; Ladefoged O; Nielsen M; Kamstrup O
    Nephron; 1983; 34(3):185-91. PubMed ID: 6877450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy of uremic osteopathy. II. Effect of 5,6-trans-25-hydroxycholecalciferol in terminal kidney insufficiency].
    von Herrath D; Kraft D; Grigoleit HG; Schaefer K
    Dtsch Med Wochenschr; 1973 Jul; 98(28):1379-81. PubMed ID: 4197778
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.